Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
Modified release formulations of gamma-hydroxybutyrate having improved dissolution and pharmacokinetic properties are provided, and therapeutic uses thereof.
1. A pharmaceutical formulation, comprising:
an immediate release portion comprising gamma-hydroxybutyrate;
a modified release portion comprising particles, each particle comprising gamma-hydroxybutyrate and a coating, wherein the coating comprises a methacrylic acid and methyl methacrylate copolymer, a methacrylic acid and ethyl acrylate copolymer, and hydrogenated vegetable oil; and
one or more suspending or viscosifying agents,
wherein the formulation comprises an amount of gamma-hydroxybutyrate equivalent to from 3.0 g to 12.0 g of sodium oxybate, and
wherein the formulation is designed to be administered orally only once nightly.
2. The pharmaceutical formulation of claim 1 , wherein the one or more suspending or viscosifying agents comprises 1% to 15% (w/w) of the formulation.
3. The pharmaceutical formulation of claim 1 , wherein the one or more suspending or viscosifying agents comprises 2% to 10% (w/w) of the formulation.
4. The pharmaceutical formulation of claim 1 , wherein the one or more suspending or viscosifying agents comprises 2% to 5% (w/w) of the formulation.
5. The pharmaceutical formulation of claim 1 , wherein the one or more suspending or viscosifying agents comprises 2% to 3% (w/w) of the formulation.
6. The pharmaceutical formulation of claim 1 , wherein the one or more suspending or viscosifying agents is selected from the group consisting of xanthan gum, medium viscosity sodium carboxymethyl cellulose, mixtures of microcrystalline cellulose and sodium carboxymethyl cellulose, mixtures of microcrystalline cellulose and guar gum, medium viscosity hydroxyethyl cellulose, agar, sodium alginate, mixtures of sodium alginate and calcium alginate, gellan gum, carrageenan gum grade iota, kappa or lambda, medium viscosity hydroxypropylmethyl cellulose, and mixtures thereof.
7. A pharmaceutical formulation, comprising:
an immediate release portion comprising gamma-hydroxybutyrate;
a modified release portion comprising particles, each particle comprising gamma-hydroxybutyrate and a coating, wherein the coating comprises a methacrylic acid and methyl methacrylate copolymer, a methacrylic acid and ethyl acrylate copolymer, and hydrogenated vegetable oil; and
a suspending or viscosifying agent comprising one or more of carrageenan gum, hydroxyethyl cellulose or xanthan gum,
wherein the formulation comprises an amount of gamma-hydroxybutyrate equivalent to from 3.0 g to 12.0 g of sodium oxybate.
8. The pharmaceutical formulation of claim 7 , wherein the suspending or viscosifying agent comprises carrageenan gum, hydroxyethyl cellulose, and xanthan gum.
9. The pharmaceutical formulation of claim 7 , wherein the suspending or viscosifying agent comprises carrageenan gum.
10. The pharmaceutical formulation of claim 7 , wherein the suspending or viscosifying agent comprises xanthan gum.
11. The pharmaceutical formulation of claim 7 , wherein the suspending or viscosifying agent comprises hydroxyethyl cellulose.
12. The pharmaceutical formulation of claim 7 , wherein the coating is 10 to 50% of the weight of the particles.
13. The pharmaceutical formulation of claim 7 , wherein the coating is 15 to 45% of the weight of the particles.
14. The pharmaceutical formulation of claim 7 , wherein the coating is 20 to 40% of the weight of the particles.
15. The pharmaceutical formulation of claim 7 , wherein the coating is 25 to 35% of the weight of the particles.
16. The pharmaceutical formulation of claim 7 , wherein the coating is 30% of the weight of the particles.
17. A pharmaceutical formulation, comprising:
an immediate release portion comprising gamma-hydroxybutyrate; and
a modified release portion comprising particles, each of the particles comprising gamma-hydroxybutyrate and a coating, wherein the coating comprises:
a polymer carrying free carboxylic groups and having a pH trigger of from 5.5 to 6.97; and
a hydrophobic compound having a melting point equal or greater than 40° C., wherein a weight ratio of the hydrophobic compound to the polymer carrying free carboxylic groups is from 0.4 to 4; and
one or more suspending or viscosifying agents selected from the group consisting of xanthan gum, medium viscosity sodium carboxymethyl cellulose, mixtures of microcrystalline cellulose and sodium carboxymethyl cellulose, mixtures of microcrystalline cellulose and guar gum, medium viscosity hydroxyethyl cellulose, agar, sodium alginate, mixtures of sodium alginate and calcium alginate, gellan gum, carrageenan gum, medium viscosity hydroxypropylmethyl cellulose, and mixtures thereof.
18. A pharmaceutical formulation, comprising:
an immediate release portion comprising gamma-hydroxybutyrate;
a modified release portion comprising particles comprising gamma-hydroxybutyrate, each particle comprising a coating, wherein the coating comprises a methacrylic acid and methyl methacrylate copolymer, a methacrylic acid and ethyl acrylate copolymer; and
one or more suspending or viscosifying agents,
wherein the coating is 25%-35% of the weight of the particles,
wherein the ratio of gamma-hydroxybutyrate in the immediate release portion and the modified release portion is from 10/90 to 65/35, and
wherein the formulation is designed to be administered orally only once nightly.
19. The pharmaceutical formulation of claim 18 , wherein the formulation comprises an amount of gamma-hydroxybutyrate equivalent to 3.0 g, 4.5 g, 6.0 g, 7.5 g, 9.0 g, 10.5 g, or 12 g of sodium oxybate.
20. The pharmaceutical formulation of claim 18 , further comprising a lubricant selected from the group consisting of salts of stearic acid, magnesium stearate, calcium stearate or zinc stearate, esters of stearic acid, glyceryl monostearate or glyceryl palmitostearate, stearic acid, glycerol behenate, sodium stearyl fumarate, talc, colloidal silicon dioxide, and mixtures thereof.
21. The pharmaceutical formulation of claim 20 , wherein the lubricant is magnesium stearate.
22. The pharmaceutical formulation of claim 20 , wherein the lubricant comprises 0.1% to 5% (w/w) of the formulation.
23. The pharmaceutical formulation of claim 20 , wherein the lubricant comprises about 0.5% of the formulation.